YieldMax MRNA Option Income Strategy ETF (MRNY)

The long-term outlook is catastrophic. This instrument has suffered a structural collapse, dropping nearly 92% over the last two years with two consecutive years of severe declines. The business model appears to be failing, evidenced by the precipitous drop in share price and the fact that recent distributions are barely covering the massive capital loss incurred by holders. While the headline yield is grotesquely high at 17.8%, this is a classic value trap; the payout is likely eroding shareholder value rather than providing sustainable income, as the fund trades at a fraction of its historical value. Short-term momentum is weak, with the stock trading well below its 50-day average despite a recent bounce, and options flow confirms that smart money is buying insurance against further ruin. Avoid this security entirely.